|
|
|
|
| LEADER |
02427nam a2200265 u 4500 |
| 001 |
EB002001935 |
| 003 |
EBX01000000000000001164836 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
210907 r ||| eng |
| 245 |
0 |
0 |
|a CADTH Canadian drug expert committee recommendation: Naltrexone hydrochloride and bupropion hydrochloride (Contrave -- Bausch Health, Canada Inc.)
|h Elektronische Ressource
|b indication: an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index of 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbidity (e.g., controlled hypertension, type 2 diabetes mellitus, or dyslipidemia)
|
| 246 |
3 |
1 |
|a Naltrexone hydrochloride and bupropion hydrochloride (Contrave -- Bausch Health, Canada Inc.)
|
| 246 |
3 |
1 |
|a Drug reimbursement recommendation Naltrexone hydrochloride and bupropion hydrochloride (Contrave)
|
| 250 |
|
|
|a Version: 1.0
|
| 260 |
|
|
|a Ottawa (ON)
|b Canadian Agency for Drugs and Technologies in Health
|c 2020, June 2020
|
| 300 |
|
|
|a 1 PDF file (9 pages)
|
| 710 |
2 |
|
|a CADTH Canadian Drug Expert Committee
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH common drug review
|
| 500 |
|
|
|a "Final."
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK565294
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a Contrave (naltrexone hydrochloride plus bupropion hydrochloride) has a Health Canada indication as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial BMI of:30 kg/m2 or greater (obese) or27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbidity (e.g., controlled hypertension, type 2 diabetes mellitus, or dyslipidemia).Naltrexone is an opioid antagonist and bupropion is a relatively weak inhibitor of the neuronal reuptake of dopamine and norepinephrine. Contrave is available as a fixed-dose combination of naltrexone hydrochloride 8 mg and bupropion hydrochloride 90 mg extended-release tablets for oral administration and the Health Canada-approved dosage is two tablets twice daily for a total daily dose of 32 mg of naltrexone hydrochloride and 360 mg of bupropion hydrochloride
|